Boston, MA – According to filings with the U.S. Securities and Exchange Commission, OcuTerra Therapeutics is raising $50,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kerrie Brady played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OcuTerra Therapeutics
Diabetic retinopathy in the US is projected to almost double by 20302. With no non-invasive treatments available the current standard of care is active surveillance until a sight threatening complication arises or vision deteriorates past a certain threshold at which point anti-VEGF intravitreal injections are commenced. These injections into the back of the eye are required every month or so for the rest of the patients life or until resistance develops. Our topical compound, OTT166, is designed to be administered as an eye drop by the patient at home to treat diabetic retinopathy earlier to preserve vision. By enabling earlier non-invasive treatment our goal is to prevent progression, thereby delaying or completely eliminating the need for intravitreal injections.

To learn more about OcuTerra Therapeutics, visit http://www.ocuterratx.com/

Contact:
Kerrie Brady, Chief Executive Officer
339-234-1333
https://www.linkedin.com/in/kerrie-brady/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved